The positive correlation between a high number of CD3+ and CD8+/TILs, and clinical outcomes indicates its potential as a useful biomarker in HNSCC patients treated with definitive chemoradiotherapy [5]. This evidence concerns the gene CD8A and head and neck squamous cell carcinoma.